The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Engleman Edgar since 2014.
This trader's CIK number is 1227162.
At the time of last reporting, Engleman Edgar was the Director of Bolt Biotherapeutics, Inc.. (stock ticker symbol BOLT).
Also see all insider trading activities at Bolt Biotherapeutics, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2023 | BOLT | 0 | $0 | 200,000 | $176,404 | 0 | $0 |
| 2021 | BOLT | 200,000 | $4,000,000 | 164 | $3,280 | 0 | $0 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2017 | SLNO | 2,573,693 | $2,714,881 | 0 | $0 | 0 | $0 |
| 2014 | SLNO | 2,939,611 | $0 | 11,294,121 | $0 | 0 | $0 |
1. Bolt Biotherapeutics, Inc. (BOLT)
2. Soleno Therapeutics Inc (SLNO)
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2023-11-29 | BOLT | Sale | 25,805 | .91 | 23,379 |
| 2023-11-30 | BOLT | Sale | 123,079 | .86 | 105,601 |
| 2023-11-21 | BOLT | Sale | 1,943 | .90 | 1,750 |
| 2023-11-17 | BOLT | Sale | 9,345 | .93 | 8,690 |
| 2023-11-20 | BOLT | Sale | 31,257 | .92 | 28,756 |
| 2023-11-16 | BOLT | Sale | 8,571 | .96 | 8,228 |
| 2021-02-09 | BOLT | Buy | 200,000 | 20.00 | 4,000,000 |
| 2021-02-09 | BOLT | Sale | 164 | 20.00 | 3,280 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2017-12-15 | SLNO | Buy | 1,085,480 | 1.84 | 2,000,539 |
| 2017-03-07 | CAPN | Buy | 1,488,213 | .48 | 714,342 |
| 2014-11-18 | CAPN | Buy | 2,939,611 | .00 | 0 |
| 2014-11-18 | CAPN | Sale | 11,294,121 | .00 | 0 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Engleman Edgar (Director of Bolt Biotherapeutics, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.